All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.
OCEAN phase III trial: Why the initial efficacy observed with melflufen + dex has not improved OS
Withdrawal of melflufen in combination with dexamethasone for patients with RRMM in the U.S.
On October 22, 2021, melphalan flufenamide, also known as melflufen, was withdrawn in the U.S. for relapsed or refractory multiple myeloma (R/R MM).
EHA 2019 | Updated analysis from the HORIZON study of melflufen in RRMM
Paul G. Richardson from the Dana-Farber Cancer Institute, Boston, US, speaks to the Multiple Myeloma Hub about the updated analysis from the HORIZON study of melflufen in RRMM.
Subscribe to get the best content related to multiple myeloma delivered to your inbox